emtricitabine by Cipla USA Inc. / CIPLA LIMITED GOA / CIPLA LIMITED KURKUMBH EMTRICITABINE capsule

emtricitabine by

Drug Labeling and Warnings

emtricitabine by is a Prescription medication manufactured, distributed, or labeled by Cipla USA Inc., CIPLA LIMITED GOA, CIPLA LIMITED KURKUMBH. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • BOXED WARNING (What is this?)

    WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B

    Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued emtricitabine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue emtricitabine. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1)].

  • 1 INDICATIONS AND USAGE

    Emtricitabine is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Testing Prior to Initiation of Treatment with Emtricitabine

    Prior to or when initiating emtricitabine, test patients for hepatitis B virus infection [see Warnings and Precautions (5.1)].

    2.2 Recommended Dosage

    Emtricitabine is taken by mouth once daily and may be taken without regard to food [see Clinical Pharmacology (12.3)].

    2.3 Recommended Dosage in Adult Patients (18 years of age and older)

    Emtricitabine capsules: One 200 mg capsule administered once daily orally.

    2.5 Recommended Dosage in Pediatric Patients (3 months through 17 years of age)

    Emtricitabine capsules: For pediatric patients weighing more than 33 kg who can swallow an intact capsule, one 200 mg capsule administered once daily orally.

    2.6 Dosage Adjustment in Patients with Renal Impairment

    Table 1 provides dosage interval adjustment for patients with renal impairment. No dosage adjustment is necessary for patients with mild renal impairment (creatinine clearance 50–80 mL/min). The safety and effectiveness of dose adjustment recommendations in patients with moderate to severe renal impairment (creatinine clearance below 50 mL/min) have not been clinically evaluated. Therefore, clinical response to treatment and renal function should be closely monitored in these patients [see Warnings and Precautions (5.4), Use in Specific Populations (8.6)].

    Table 1. Dose Interval Adjustment for Adult Patients with Altered Creatinine Clearance
    FormulationCreatinine Clearance (mL/min)

    ≥50 mL/min

    30–49 mL/min

    15–29 mL/min

    <15 mL/min or on hemodialysisa

    Capsule (200 mg)

    200 mg every 24 hours

    200 mg every 48 hours

    200 mg every 72 hours

    200 mg every 96 hours

    a. Hemodialysis Patients: If dosing on day of dialysis, give dose after dialysis.

    There are insufficient data available to make dosage recommendations in pediatric patients with renal impairment.

  • 3 DOSAGE FORMS AND STRENGTHS

    Emtricitabine Capsules, containing 200 mg of emtricitabine, are size '1' capsules with sky blue cap imprinted with "EMT" in black and white body imprinted with "200" in black.

  • 4 CONTRAINDICATIONS

    Emtricitabine is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the products.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV

    All patients should be tested for the presence of chronic Hepatitis B virus (HBV) before or when initiating emtricitabine [see Dosage and Administration (2.1)].

    Severe acute exacerbations of hepatitis B (e.g., liver decompensation and liver failure) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued emtricitabine. Patients who are coinfected with HIV-1 and HBV who discontinue emtricitabine should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. If appropriate, initiation of anti-hepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis, since posttreatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure.

    5.2 Immune Reconstitution Syndrome

    Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including emtricitabine. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus , Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.

    Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.

    5.3 Lactic Acidosis/Severe Hepatomegaly with Steatosis

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. Treatment with emtricitabine should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).

    5.4 Dose Adjustment in Patients with New Onset or Worsening Renal Impairment

    Emtricitabine is principally eliminated by the kidney. Reduction of the dosage of emtricitabine is recommended for patients with impaired renal function [see Dosage and Administration (2.6), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].

  • 6 ADVERSE REACTIONS

    The following adverse reactions are discussed in other sections of the labeling:

    • Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV [see Warnings and Precautions (5.1)] .
    • Immune Reconstitution Syndrome [see Warnings and Precautions (5.2)]
    • Lactic Acidosis/Severe Hepatomegaly with Steatosis [see Warnings and Precautions (5.3)] .

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    Adverse Reactions from Clinical Trials Experience in Adults

    More than 2,000 adult subjects with HIV-1 infection have been treated with emtricitabine alone or in combination with other antiretroviral agents for periods of 10 days to 200 weeks in clinical trials.

    The most common adverse reactions (incidence greater than or equal to 10%, any severity) identified from any of the three large, controlled clinical trials include headache, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, and rhinitis.

    In Trials 301A and 303, the most common adverse reactions that occurred in subjects receiving emtricitabine with other antiretroviral agents were headache, diarrhea, nausea, and rash, which were generally mild to moderate. Approximately 1% of subjects discontinued participation in the clinical trials due to these events. All adverse reactions were reported with similar frequency in emtricitabine and control treatment groups except for skin discoloration, which was reported with higher frequency in the emtricitabine treated group.

    Skin discoloration, manifested by hyperpigmentation on the palms or soles, was generally mild and asymptomatic. The mechanism and clinical significance are unknown.

    A summary of emtricitabine treatment-emergent clinical adverse reactions in Trials 301A and 303 is provided in Table 2.

    Table 2. Selected Treatment-Emergent Adverse Reactions (All Grades, Regardless of Causality) Reported in ≥ 3% of Emtricitabine-Treated Subjects in Either Trial 301A or 303 (0–48 Weeks)
     303301A

    Emtricitabine+ AZT/d4T + NNRTI/PI
    (N=294)

    3TC + AZT/d4T + NNRTI/PI
    (N=146)

    Emtricitabine + didanosine + EFV
    (N=286)

    d4T + didanosine + EFV
    (N=285)

    Body as a Whole

     

     

     

     

    Asthenia

    16%

    10%

    12%

    17%

    Headache

    13%

    6%

    22%

    25%

    Abdominal pain

    8%

    11%

    14%

    17%

    Digestive System

     

     

     

     

    Diarrhea

    23%

    18%

    23%

    32%

    Nausea

    18%

    12%

    13%

    23%

    Vomiting

    9%

    7%

    9%

    12%

    Dyspepsia

    4%

    5%

    8%

    12%

    Musculoskeletal

     

     

     

     

    Myalgia

    4%

    4%

    6%

    3%

    Arthralgia

    3%

    4%

    5%

    6%

    Nervous System

     

     

     

     

    Insomnia

    7%

    3%

    16%

    21%

    Depressive disorders

    6%

    10%

    9%

    13%

    Paresthesia

    5%

    7%

    6%

    12%

    Dizziness

    4%

    5%

    25%

    26%

    Neuropathy/peripheral neuritis

    4%

    3%

    4%

    13%

    Abnormal dreams

    2%

    <1%

    11%

    19%

    Respiratory

     

     

     

     

    Rhinitis

    18%

    12%

    12%

    10%

    Increased cough

    14%

    11%

    14%

    8%

    Skin

     

     

     

     

    Rash eventa

    17%

    14%

    30%

    33%

    AZT=zidovudine; d4T=stavudine; NNRTI/PI=non-nucleoside reverse transcriptase inhibitor/protease inhibitor;

    3TC=lamivudine; EFV=efavirenz.

    a. Rash event includes rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash, and allergic reaction.

    Laboratory Abnormalities: Laboratory abnormalities in these trials occurred with similar frequency in the emtricitabine and comparator groups. A summary of Grades 3-4 laboratory abnormalities is provided in Table 3.

    Table 3. Treatment-Emergent Grades 3-4 Laboratory Abnormalities Reported in ≥1% of Emtricitabine-Treated Subjects in Either Trial 301A or 303

     

    303

    301A

    Emtricitabine + AZT/d4T + NNRTI/PI (N=294)

    3TC + AZT/d4T + NNRTI/PI (N=146)

    Emtricitabine + Didanosine + EFV (N=286)

    d4T + Didanosine + EFV (N=285)

    Any ≥ Grade 3 Laboratory Abnormality

    31%

    28%

    34%

    38%

    ALT (>5.0 × ULNa)

    2%

    1%

    5%

    6%

    AST (>5.0 × ULN)

    3%

    <1%

    6%

    9%

    Bilirubin (>2.5 × ULN)

    1%

    2%

    <1%

    <1%

    Creatine kinase (>4.0 × ULN)

    11%

    14%

    12%

    11%

    Neutrophils (<750 mm3)

    5%

    3%

    5%

    7%

    Pancreatic amylase (>2.0 × ULN)

    2%

    2%

    <1%

    1%

    Serum amylase (>2.0 × ULN)

    2%

    2%

    5%

    10%

    Serum glucose <40 or >250 mg/dL)

    3%

    3%

    2%

    3%

    Serum lipase (>2.0 × ULN)

    <1%

    <1%

    1%

    2%

    Triglycerides (>750 mg/dL)

    10%

    8%

    9%

    6%

    a. ULN = Upper limit of normal

    In Trial 934, 511 antiretroviral-naïve subjects received efavirenz (EFV) administered in combination with either emtricitabine + tenofovir disoproxil fumarate (TDF) (N=257) or AZT/3TC (N=254) for 144 weeks. The most common adverse reactions (incidence greater than or equal to 10%, all grades) included diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash. Table 4 provides the treatment-emergent adverse reactions (Grades 2−4) occurring in greater than or equal to 5% of subjects treated in any treatment group.

    Table 4. Selected Adverse Reactionsa (Grades 2–4) Reported in ≥ 5% in Any Treatment Group in Trial 934 (0–144 Weeks)
     Emtricitabine + TDF + EFVbAZT/3TC + EFV

    N=257

    N=254

    Fatigue

    9%

    8%

    Depression

    9%

    7%

    Nausea

    9%

    7%

    Diarrhea

    9%

    5%

    Dizziness

    8%

    7%

    Upper respiratory tract infections

    8%

    5%

    Sinusitis

    8%

    4%

    Rash eventc

    7%

    9%

    Headache

    6%

    5%

    Insomnia

    5%

    7%

    Nasopharyngitis

    5%

    3%

    Vomiting

    2%

    5%

    a. Frequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to study drug.

    b. From Weeks 96 to 144 of the trial, subjects received TRUVADA® with EFV in place of emtricitabine +TDF with EFV.

    c. Rash event includes rash, exfoliative rash, rash generalized, rash macular, rash maculo-papular, rash pruritic, and rash vesicular.

    Laboratory Abnormalities: Laboratory abnormalities observed in Trial 934 were generally consistent with those seen in previous trials (Table 5).

    Table 5. Significant Laboratory Abnormalities Reported in ≥1% of Subjects in Any Treatment Group in Trial 934 (0–144 Weeks)
     Emtricitabine + TDF+ EFVaAZT/3TC + EFV

    N=257

    N=254

    Any ≥ Grade 3 Laboratory Abnormality

    30%

    26%

    Fasting Cholesterol (>240 mg/dL)

    22%

    24%

    Creatine Kinase
    (M: >990 U/L)
    (F: >845 U/L)

    9%

    7%

    Serum Amylase (>175 U/L)

    8%

    4%

    Alkaline Phosphatase (>550 U/L)

    1%

    0%

    AST
    (M: >180 U/L)
    (F: >170 U/L)

    3%

    3%

    ALT
    (M: >215 U/L)
    (F: >170 U/L)

    2%

    3%

    Hemoglobin (<8.0 mg/dL)

    0%

    4%

    Hyperglycemia (>250 mg/dL)

    2%

    1%

    Hematuria (>75 RBC/HPF)

    3%

    2%

    Glycosuria (3+)

    <1%

    1%

    Neutrophils (<750/mm3)

    3%

    5%

    Fasting Triglycerides (>750mg/dL)

    4%

    2%

    a. From Weeks 96 to 144 of the trial, subjects received TRUVADA with EFV in place of emtricitabine +TDF with EFV.

    Adverse Reactions from Clinical Trials Experience in Pediatric Subjects

    Assessment of adverse reactions in pediatric subjects is based on data from Trial 203, an open label, uncontrolled trial of 116 HIV-1 infected subjects who received FTC through 48 weeks. The adverse reaction profile in pediatric subjects was generally comparable to that observed in clinical trials of emtricitabine in adult subjects [see Adverse Reactions (6.1)]. Hyperpigmentation was more frequent in children. Additional adverse reactions identified from this trial include anemia.

    Selected treatment-emergent adverse events, regardless of causality, reported in subjects during 48 weeks of treatment were the following: infection (44%), hyperpigmentation (32%), increased cough (28%), vomiting (23%), otitis media (23%), rash (21%), rhinitis (20%), diarrhea (20%), fever (18%), pneumonia (15%), gastroenteritis (11%), abdominal pain (10%), and anemia (7%). Treatment-emergent Grades 3-4 laboratory abnormalities were experienced by 9% of pediatric subjects, including elevated amylase (>2.0 x ULN) (n=4), decreased neutrophils (<750/mm3) (n=3), elevated ALT (>5 x ULN) (n=2), elevated CPK (>4 x ULN) (n=2) and one subject each with elevated bilirubin (>3.0 x ULN), elevated GGT (>10 x ULN), elevated lipase (>2.5 x ULN), decreased hemoglobin (<7 g/dL), and decreased glucose (<40 mg/dL).

  • 7 DRUG INTERACTIONS

    The potential for drug interactions with emtricitabine has been studied in combination with AZT, indinavir, d4T, famciclovir, and tenofovir DF (TDF). There were no clinically significant drug interactions for any of these drugs. Drug interactions trials are described elsewhere in the labeling [see Clinical Pharmacology (12.3)].

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Exposure Registry

    There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to emtricitabine during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.

    Risk Summary

    Available data from the APR show no increase in the overall risk of major birth defects with first trimester exposure for emtricitabine (FTC) (2.3%) compared with the background rate for major birth defects of 2.7% in a U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) (see Data). The rate of miscarriage for individual drugs is not reported in the APR. In the U.S., general population, the estimated background risk of miscarriage in clinically recognized pregnancies is 15–20%.

    In animal reproduction studies, no adverse developmental effects were observed when FTC was administered at exposures ≥60 times that of the recommended daily dose of emtricitabine (see Data).

    Data

    Human Data

    Based on prospective reports to the APR of exposures to FTC-containing regimens during pregnancy resulting in live births (including over 2,700 exposed in the first trimester and over 1,200 exposed in the second/third trimester), there was no increase between FTC and overall birth defects compared with the background birth defect rate of 2.7% in a U.S. reference population of the MACDP. The prevalence of birth defects in live births was 2.4% (95% CI: 1.9% to 3.1%) with first trimester exposure to FTC-containing regimens and 2.3% (95% CI: 1.5% to 3.3%) with the second/third trimester exposure to FTC-containing regimens.

    Prospective reports from the APR of overall major birth defects in pregnancies exposed to FTC are compared with a U.S. background major birth defect rate. Methodologic limitations of the APR include the use of MACDP as the external comparator group. Limitations of using an external comparator include differences in methodology and populations, as well as confounding due to the underlying disease.

    Additionally, published observational studies on FTC exposure in pregnancy have not shown an increased risk for major malformations.

    Animal Data

    FTC was administered orally to pregnant mice (at 0, 250, 500, or 1,000 mg/kg/day), and rabbits (at 0, 100, 300, or 1,000 mg/kg/day) through organogenesis (on gestation days 6 through 15, and 7 through 19, respectively). No significant toxicological effects were observed in embryo-fetal toxicity studies performed with FTC in mice at exposures (AUC) approximately 60 times higher and in rabbits at approximately 120 times higher than human exposures at the recommended daily dose. In a pre/postnatal development study in mice, FTC was administered orally at doses up to 1,000 mg/kg/day; no significant adverse effects directly related to drug were observed in the offspring exposed daily from before birth (in utero) through sexual maturity at daily exposures (AUC) of approximately 60 times higher than human exposures at the recommended daily dose.

    8.2 Lactation

    Risk Summary

    The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1. 

    Based on published data, FTC has been shown to be present in human breast milk. It is not known if FTC affects milk production or has effects on the breastfed child.

    Because of the potential for: (1) HIV transmission (in HIV-negative infants); (2) developing viral resistance (in HIV-positive infants); and (3) adverse reactions in a breastfed infant similar to those seen in adults, instruct mothers not to breastfeed if they are taking emtricitabine.

    8.4 Pediatric Use

    The safety and efficacy of FTC in patients between 3 months and 21 years of age is supported by data from three open-label, nonrandomized clinical trials in which FTC was administered to 169 HIV-1 infected treatment-naive and experienced (defined as virologically suppressed on a 3TC containing regimen for which FTC was substituted for 3TC) subjects [see Clinical Studies (14.4)].

    The pharmacokinetics of FTC were studied in 20 neonates born to HIV-1 positive mothers [see Clinical Studies (14.4)]. All neonates were HIV-1 negative at the end of the trial; the efficacy of FTC in preventing or treating HIV-1 could not be determined.

    8.5 Geriatric Use

    Clinical trials of emtricitabine did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. In general, dose selection for the elderly patient should be cautious, keeping in mind the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

    8.6 Renal Impairment

    Modify the dose or dosing interval for emtricitabine in patients with creatinine clearance below 50 mL/min or in patients with end stage renal disease requiring dialysis [see Dosage and Administration (2.6)].

  • 10 OVERDOSAGE

    If overdose occurs, the patient should be monitored for evidence of toxicity, and standard supportive treatment applied as necessary.

    Hemodialysis treatment removes approximately 30% of the FTC dose over a 3-hour dialysis period starting within 1.5 hours of FTC dosing (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min). It is not known whether FTC can be removed by peritoneal dialysis.

  • 11 DESCRIPTION

    Emtricitabine is a synthetic nucleoside analog with activity against human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.

    The chemical name of emtricitabine is 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Emtricitabine is the (-) enantiomer of a thio analog of cytidine, which differs from other cytidine analogs in that it has a fluorine in the 5-position.

    It has a molecular formula of C8H10FN3O3S and a molecular weight of 247.24. It has the following structural formula:

    Image

    Emtricitabine is a white to off-white powder with a solubility of approximately 112 mg/mL in water at 25 ºC. The log P for FTC is -0.43 and the pKa is 2.65.

    Emtricitabine capsules are for oral administration. Each capsule contains 200 mg of emtricitabine and the inactive ingredients, mannitol, hypromellose, and magnesium stearate. The capsule shell contains the following inactive ingredients and dyes: FD&C blue 1, titanium dioxide, gelatin, and sodium lauryl sulfate. The capsules are printed with ink containing black iron oxide.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Emtricitabine is an antiretroviral drug [see Microbiology (12.4)].

    12.3 Pharmacokinetics

    Adults

    The pharmacokinetic properties of FTC were evaluated in healthy subjects and HIV- 1-infected subjects. Emtricitabine pharmacokinetics are similar between these populations.

    Figure 1 shows the mean steady-state plasma FTC concentration-time profile in 20 HIV-1-infected subjects receiving emtricitabine capsules.

    Figure 1 Mean (± 95% CI) Steady-State Plasma FTC Concentrations in HIV-1-Infected Adults (N=20)

    Image

    Absorption

    Emtricitabine is rapidly and extensively absorbed following oral administration, with peak plasma concentrations occurring at 1-2 hours postdose. Following multiple dose oral administration of emtricitabine capsules to 20 HIV-1 infected subjects, the (mean ± SD) steady-state plasma FTC peak concentration (Cmax) was 1.8 ± 0.7 µg/mL and the area-under the plasma concentration-time curve over a 24-hour dosing interval (AUC) was 10.0 ± 3.1 µghr/mL. The mean steady-state plasma trough concentration at 24 hours postdose was 0.09 µg/mL. The mean absolute bioavailability of emtricitabine capsules was 93%, while the mean absolute bioavailability of emtricitabine oral solution was 75%. The relative bioavailability of emtricitabine oral solution was approximately 80% of emtricitabine capsules.

    The multiple dose pharmacokinetics of FTC are dose proportional over a dose range of 25-200 mg.

    Distribution

    In vitro binding of FTC to human plasma proteins was less than 4% and independent of concentration over the range of 0.02-200 µg/mL. At peak plasma concentration, the mean plasma to blood drug concentration ratio was ~1.0 and the mean semen to plasma drug concentration ratio was ~4.0.

    Metabolism

    Following administration of radiolabelled FTC, complete recovery of the dose was achieved in urine (~86%) and feces (~14%). Thirteen percent (13%) of the dose was recovered in urine as three putative metabolites. The biotransformation of FTC includes oxidation of the thiol moiety to form the 3'-sulfoxide diastereomers (~9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (~4% of dose). No other metabolites were identifiable.

    Elimination

    The plasma FTC half-life is approximately 10 hours. The renal clearance of FTC is greater than the estimated creatinine clearance, suggesting elimination by both glomerular filtration and active tubular secretion. There may be competition for elimination with other compounds that are also renally eliminated.

    Effects of Food on Oral Absorption

    Emtricitabine capsules may be taken with or without food. Emtricitabine systemic exposure (AUC) was unaffected while Cmax decreased by 29% when emtricitabine capsules were administered with food (an approximately 1000 kcal high-fat meal).

    Specific Populations

    Geriatric Patients

    The pharmacokinetics of FTC have not been fully evaluated in the elderly (65 years of age and older).

    Pediatric Patients

    The pharmacokinetics of FTC at steady state were determined in 77 HIV-1 infected pediatric subjects, and the pharmacokinetic profile was characterized in four age groups (Table 6). The FTC exposure achieved in pediatric subjects receiving a daily dose of 6 mg/kg up to a maximum of 240 mg oral solution or a 200 mg capsule is similar to exposures achieved in adult subjects receiving a once-daily dose of 200 mg.

    Table 6. Mean ± SD Pharmacokinetic Parameters by Age Groups for Pediatric Subjects and Neonates Receiving Emtricitabine Capsules

    a Two pharmacokinetic evaluations were conducted in 20 neonates over the first 3 months of life. Median (range) age of infant on day of pharmacokinetic evaluation was 26 (5-81) days.

    b Mean (range)

    		HIV-1-exposed Neonates
    		HIV-1-Infected Pediatric Subjects
    Age
    		0-3 mo
    (N=20)a
    		3-24 mo
    (N=14)
    		25 mo-6 yr
    (N=19)
    		7–12yr
    (N=17)
    		13–17 yr
    (N=27)
    Formulation
    Capsule (n)
    		 0
    		 0
    		 0
    		 10
    		 26
    Dose (mg/kg)b
    		3.1 (2.9-3.4)
    		 6.1 (5.5-6.8)
    		 6.1 (5.6-6.7)
    		 5.6 (3.1−6.6)
    		 4.4 (1.8−7.0)
    Cmax (µg/mL)
    		 1.6 ± 0.6
    		 1.9 ± 0.6
    		 1.9 ± 0.7
    		 2.7 ± 0.8
    		 2.7 ± 0.9
    AUC (µghr/mL)
    		 11.0 ± 4.2
    		 8.7 ± 3.2
    		 9.0 ± 3.0
    		 12.6 ± 3.5
    		 12.6 ± 5.4
    T1/2 (hr)
    		 12.1 ± 3.1
    		 8.9 ± 3.2
    		 11.3 ± 6.4
    		 8.2 ± 3.2
    		 8.9 ± 3.3

    Gender

    FTC pharmacokinetics are similar in adult male and female subjects.

    Race

    No pharmacokinetic differences due to race have been identified.

    Patients with Renal Impairment

    The pharmacokinetics of FTC are altered in subjects with renal impairment [see Warnings and Precautions (5.4)]. In adult subjects with creatinine clearance below 50 mL/min or with end-stage renal disease (ESRD) requiring dialysis, Cmax and AUC of FTC were increased (Table 7). The effects of renal impairment on FTC pharmacokinetics in pediatric patients are not known.

    Table 7. Pharmacokinetic Parameters (Mean ± SD) of FTC in Adult Subjects with Varying Degrees of Renal Function

    a. ESRD subjects requiring dialysis

    b. NA = Not Applicable
    Creatinine Clearance (mL/min)
    		>80
    (N=6)
    		50–80
    (N=6)
    		30–49
    (N=6)
    		<30
    (N=5)
    		ESRDa <30
    (N=5)
    Baseline creatinine clearance (mL/min)
    		 107 ± 21
    		 59.8 ± 6.5
    		 40.9 ± 5.1
    		 22.9 ± 5.3
    		 8.8 ± 1.4
    Cmax (µg/mL)
    		 2.2 ± 0.6
    		 3.8 ± 0.9
    		 3.2 ± 0.6
    		 2.8 ± 0.7
    		 2.8 ± 0.5
    AUC (µghr/mL)
    		 11.8 ± 2.9
    		 19.9 ± 1.2
    		 25.1 ± 5.7
    		 33.7± 2.1
    		 53.2 ± 9.9
    CL/F (mL/min)
    		 302 ± 94
    		 168 ± 10
    		 138 ± 28
    		 99 ± 6
    		 64 ± 12
    CLr (mL/min)
    		 213 ± 89
    		 121 ± 39
    		 69 ± 32
    		 30 ± 11
    		 NAb

    Patients with Hepatic Impairment

    The pharmacokinetics of FTC have not been studied in subjects with hepatic impairment; however, FTC is not significantly metabolized by liver enzymes, so the impact of liver impairment should be limited.

    Assessment of Drug Interactions

    At concentrations up to 14-fold higher than those observed in vivo, FTC did not inhibit in vitro drug metabolism mediated by any of the following human CYP isoforms: CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. FTC did not inhibit the enzyme responsible for glucuronidation (uridine-5'-disphosphoglucuronyl transferase). Based on the results of these in vitro experiments and the known elimination pathways of FTC, the potential for CYP-mediated interactions involving FTC with other medicinal products is low.

    Emtricitabine has been evaluated in healthy volunteers in combination with TDF, AZT, indinavir, famciclovir, and d4T. Tables 8 and 9 summarize the pharmacokinetic effects of coadministered drug on FTC pharmacokinetics and effects of FTC on the pharmacokinetics of coadministered drug.

    Table 8. Drug Interactions: Change in Pharmacokinetic Parameters for FTC in the Presence of the Coadministered Druga

    a. All interaction trials conducted in healthy volunteers.

    b. ↑= Increase; ⇔= No Effect; NA = Not Applicable
    Coadministered Drug
    		Dose of Coadministered Drug (mg)
    		FTC Dose (mg)
    		N
    		% Change of FTC Pharmacokinetic Parametersb
    (90% CI)
    Cmax
    		AUC
    		Cmin
    Famciclovir
    		 500 x 1
    		 200 x 1
    		 12
    		 ⇔
    		 ⇔
    		 NA
    Indinavir
    		 800 x 1
    		 200 x 1
    		 12
    		 ⇔
    		 ⇔
    		 NA
    Stavudine
    		 40 x 1
    		 200 x 1
    		 6
    		 ⇔
    		 ⇔
    		 NA
    Tenofovir DF
    		 300 once daily
    x 7 days
    		 200 once daily x 7 days
    		 17
    		 ⇔
    		 ⇔
    		 ↑ 20
    (↑ 12 to ↑ 29)
    Zidovudine
    		 300 twice daily x 7 days
    		 200 once daily x 7 days
    		 27
    		 ⇔
    		 ⇔
    		 ⇔
    Table 9. Drug Interactions: Change in Pharmacokinetic Parameters for Coadministered Drug in the Presence of FTCa

    a. All interaction trials conducted in healthy volunteers.

    b. ↑= Increase; ⇔= No Effect; NA = Not Applicable
    Coadministered Drug
    		Dose of Coadministered Drug (mg)
    		FTC Dose (mg)
    		N
    		% Change of Coadministered Drug Pharmacokinetic Parametersb
    (90% CI)
    Cmax
    		AUC
    		Cmin
    Famciclovir
    		500 x 1
    		 200 x 1
    		 12
    		 ⇔
    		 ⇔
    		 NA
    Indinavir
    		800 x 1
    		 200 x 1
    		 12
    		 ⇔
    		 ⇔
    		 NA
    Stavudine
    		40 x 1
    		 200 x 1
    		 6
    		 ⇔
    		 ⇔
    		 NA
    Tenofovir DF
    		300 once daily
    x 7 days
    		 200 once daily x 7 days
    		 17
    		 ⇔
    		 ⇔
    		 ⇔
    Zidovudine
    		300 twice daily x 7 days
    		 200 once daily x 7 days
    		 27
    		 ↑ 17
    (↑ 0 to ↑ 38)
    		 ↑ 13
    (↑ 5 to↑ 20)
    		 ⇔

    12.4 Microbiology

    Mechanism of Action

    FTC, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate (FTC-TP), which inhibits the activity of the HIV-1 reverse transcriptase (RT) by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA resulting in chain termination. FTC-TP is a weak inhibitor of mammalian DNA polymerases α, β, ε, and mitochondrial DNA polymerase γ.

    Antiviral Activity

    The antiviral activity of FTC against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI-CCR5 cell line, and peripheral blood mononuclear cells. The 50% effective concentration (EC50) values for FTC were in the range of 0.0013-0.64 μM (0.0003-0.158 µg/mL). The median EC50, range, and number of isolates for the laboratory isolates were 0.07, 0.009−0.62, 10; 0.011, 0.002−0.03, 12; 0.055, 0.0015−0.09, 4 respectively for lymphoblastoid, PBMC, and reporter cells. The median EC50, range, and number of isolates for the clinical isolates were 0.05, 0.0105−0.64, 15; 0.015, 0.004−0.028, 6 respectively for lymphoblastoid cells and PBMCs. No antagonism was observed in drug combination studies of emtricitabine with nucleoside reverse transcriptase inhibitors (NRTIs) (abacavir, lamivudine, stavudine, tenofovir, zidovudine), non-nucleoside reverse transcriptase inhibitors (NNRTIs) (delavirdine, efavirenz, nevirapine), and protease inhibitors (amprenavir, nelfinavir, ritonavir, saquinavir). FTC displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC50 values ranged from 0.007-0.075 μM) and showed strain-specific activity against HIV-2 (EC50 values ranged from 0.007-1.5 μM in PBMCs and MAGI cells).

    Resistance

    FTC-resistant isolates of HIV-1 have been selected in cell culture and in vivo. Genotypic analysis of these isolates showed that the reduced susceptibility to FTC was associated with a valine or isoleucine (M184V/I) substitution in the HIV-1 RT.

    FTC-resistant isolates of HIV-1 have been recovered from some subjects treated with FTC alone or in combination with other antiretroviral agents. In a clinical trial of treatment-naive subjects treated with emtricitabine, didanosine, and efavirenz (EFV) [see Clinical Studies (14.2)], viral isolates from 37.5% of subjects with virologic failure showed reduced susceptibility to FTC. Genotypic analysis of these isolates showed that the resistance was due to M184V/I substitutions in the HIV-1 RT.

    In a clinical trial of treatment-naive subjects treated with either emtricitabine, TDF, and EFV or AZT/3TC and EFV [see Clinical Studies (14.2)], resistance analysis was performed on HIV-1 isolates from all confirmed virologic failure subjects with greater than 400 copies/mL of HIV-1 RNA at Week 144 or early discontinuation. Development of EFV resistance-associated substitutions occurred most frequently and was similar between the treatment arms. The M184V amino acid substitution, associated with resistance to emtricitabine and 3TC, was observed in 2/19 analyzed subject isolates in the emtricitabine + TDF group and in 10/29 analyzed subject isolates in the AZT/3TC group. Through 144 weeks of Trial 934, no subjects have developed a detectable K65R substitution in their HIV-1 as analyzed through standard genotypic analysis.

    Cross Resistance

    Cross-resistance among certain NRTIs has been recognized. FTC-resistant isolates (M184V/I) were cross-resistant to 3TC but retained susceptibility in cell culture to AZT, didanosine, d4T, and tenofovir, and to NNRTIs (delavirdine, EFV, and nevirapine). HIV-1 isolates containing the K65R substitution, selected in vivo by abacavir, didanosine, and tenofovir, demonstrated reduced susceptibility to inhibition by FTC. Viruses harboring substitutions conferring reduced susceptibility to AZT and d4T (M41L, D67N, K70R, L210W, T215Y/F, K219Q/E) or didanosine (L74V) remained sensitive to FTC. HIV-1 containing the K103N substitution associated with resistance to NNRTIs was susceptible to FTC.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    In long-term oral carcinogenicity studies of FTC, no drug-related increases in tumor incidence were found in mice at doses up to 750 mg/kg/day (26 times the human systemic exposure at the therapeutic dose of 200 mg/day) or in rats at doses up to 600 mg/kg/day (31 times the human systemic exposure at the therapeutic dose).

    Emtricitabine was not genotoxic in the reverse mutation bacterial test (Ames test) or mouse lymphoma or mouse micronucleus assays.

    Emtricitabine did not affect fertility in male rats at approximately 140-fold or in male and female mice at approximately 60-fold higher exposures (AUC) than in humans given the recommended 200 mg daily dose. Fertility was normal in the offspring of mice exposed daily from before birth (in utero) through sexual maturity at daily exposures (AUC) of approximately 60-fold higher than human exposures at the recommended 200 mg daily dose.

  • 14 CLINICAL STUDIES

    14.1 Overview of Clinical Trials

    The efficacy and safety of emtricitabine were evaluated in the trials summarized in Table 10.

    Table 10 Trials Conducted with Emtricitabine in Adult and Pediatric Subjects

     

    TrialPopulationTrial Arms (N)aTimepoint(Weeks)

    Trial 934b

    (NCT00112047)

    HIV-1 treatment-naïve adults

    Emtricitabine+TDF+EFV (227) AZT/3TC+EFV (229)

    144

    Trial 301Ac

    (NCT00006208)

    Emtricitabine +didanosine+EFV (286) d4T+didanosine+EFV (285)

    48

    Trial 303b

    (NCT00002416)

    HIV-1 treatment-experienced adults

    Emtricitabine +AZT/d4T+NNRTI/PI (294) 3TC+AZT/d4T+NNRTI/PI (146)

    48

    Trial 202d

    (NCT00016718)

    HIV-1 treatment-naïve and experienced pediatrics

    Emtricitabine +didanosine+EFV (43)

    48

    Trial 203d

    (NCT00743340)

    Emtricitabine +d4T+lopinavir/ritonavir (116)

    48

    Trial 211d

    (NCT00642291)

    Emtricitabine +didanosine+EFV (16)

    48

    a. Randomized and dosed.

    b. Randomized, open-label, active-controlled trial.

    c. Randomized, double-blind, active-controlled trial.

    d. Nonrandomized, open-label trial.

     

    14.2 Clinical Trial Results in Treatment-Naive Adults

    Trial 934

    Data through 144 weeks are reported for Trial 934, a randomized, open-label, active-controlled multicenter clinical trial comparing Emtricitabine + TDF administered in combination with EFV versus AZT/3TC fixed-dose combination administered in combination with EFV in 511 antiretroviral-naive subjects. From Weeks 96 to 144 of the trial, subjects received FTC/TDF fixed-dose combination with EFV in place of emtricitabine + TDF with EFV. Subjects had a mean age of 38 years (range 18-80); 86% were male, 59% were Caucasian, and 23% were Black. The mean baseline CD4+ cell count was 245 cells/mm3 (range 2-1191) and median baseline plasma HIV-1 RNA was 5.01 log10 copies/mL (range 3.56-6.54). Subjects were stratified by baseline CD4+ cell count (< or ≥200 cells/mm3); 41% had CD4+ cell counts <200 cells/mm3 and 51% of subjects had baseline viral loads >100,000 copies/mL. Table 11 provides treatment outcomes through 48 and 144 weeks for those subjects who did not have EFV resistance at baseline.

    Table 11 Virologic Outcomes of Randomized Treatment at Week 48 and 144 (Trial 934)

    a. Subjects who were responders at Week 48 or Week 96 (HIV-1 RNA <400 copies/mL) but did not consent to continue in the trial after Week 48 or Week 96 were excluded from analysis.

    b. Subjects achieved and maintained confirmed HIV-1 RNA <400 copies/mL through Weeks 48 and 144.

    c. Includes confirmed viral rebound and failure to achieve confirmed <400 copies/mL through Weeks 48 and 144.

    d. Includes lost to follow-up, subject withdrawal, noncompliance, protocol violation and other reasons.
    Outcomes
    		Week 48
    		Week 144
    Emtricitabine +TDF +EFV
    (N=244)
    		AZT/3TC +EFV
    (N=243)
    		Emtricitabine + TDF +EFV
    (N=227)a
    		AZT/3TC +EFV
    (N=229)a
    Responderb
    		84%
    		 73%
    		 71%
    		 58%
    Virologic failurec
    		2%
    		 4%
    		 3%
    		 6%
    Rebound
    		 1%
    		 3%
    		 2%
    		 5%
    Never suppressed
    		 0%
    		 0%
    		 0%
    		 0%
    Change in antiretroviral regimen
    		 1%
    		 1%
    		 1%
    		 1%
    Death
    		 <1%
    		 1%
    		 1%
    		 1%
    Discontinued due to adverse event
    		 4%
    		 9%
    		 5%
    		 12%
    Discontinued for other reasonsd
    		10%
    		 14%
    		 20%
    		 22%

    Through Week 48, 84%, and 73% of subjects in the emtricitabine + TDF group and the AZT/3TC group, respectively, achieved and maintained HIV-1 RNA <400 copies/mL (71% and 58% through Week 144). The difference in the proportion of subjects who achieved and maintained HIV-1 RNA <400 copies/mL through 48 weeks largely results from the higher number of discontinuations due to adverse events and other reasons in the AZT/3TC group in this open-label trial. In addition, 80% and 70% of subjects in the emtricitabine + TDF group and the AZT/3TC group, respectively, achieved and maintained HIV-1 RNA <50 copies/mL through Week 48 (64% and 56% through Week 144). The mean increase from baseline in CD4+ cell count was 190 cells/mm3 in the emtricitabine + TDF group and 158 cells/mm3 in the AZT/3TC group at Week 48 (312 and 271 cells/mm3 at Week 144).

    Through 48 weeks, 7 subjects in the emtricitabine + TDF group and 5 subjects in the AZT/3TC group experienced a new CDC Class C event (10 and 6 subjects through 144 weeks).

    Trial 301A

    Trial 301A was a 48-week double-blind, active-controlled, multicenter clinical trial comparing emtricitabine (200 mg once daily) administered in combination with didanosine and EFV versus d4T, didanosine, and EFV in 571 antiretroviral naïve adult subjects. Subjects had a mean age of 36 years (range 18-69); 85% were male, 52% Caucasian, 16% African-American, and 26% Hispanic. Subjects had a mean baseline CD4+ cell count of 318 cells/mm3 (range 5-1317) and a median baseline plasma HIV-1 RNA of 4.9 log10 copies/mL (range 2.6-7.0). Thirty-eight percent of subjects had baseline viral loads >100,000 copies/mL and 31% had CD4+ cell counts <200 cells/mL. Table 12 provides treatment outcomes through 48 weeks.

    Table 12. Virologic Outcomes of Randomized Treatment at Week 48 (Trial 301A)

    a. Subjects achieved and maintained confirmed HIV RNA <400 copies/mL (<50 copies/mL) through Week 48.

    b. Includes subjects who failed to achieve virologic suppression or rebounded after achieving virologic suppression.

    c. Includes lost to follow-up, subject withdrawal, non-compliance, protocol violation, and other reasons.
    Outcomes
    		Emtricitabine +
    Didanosine + EFV
    (N=286)
    		d4T +
    Didanosine + EFV
    (N=285)
    Respondera
    		81% (78%)
    		 68% (59%)
    Virologic Failureb
    		3%
    		 11%
    Death
    		 0%
    		 <1%
    Discontinuation Due to Adverse Event
    		 7%
    		 13%
    Discontinuation for Other Reasonsc
    		9%
    		 8%

    The mean increase from baseline in CD4+cell count was 168 cells/mm3 for the emtricitabine arm and 134 cells/mm3 for the d4T arm.

    Through 48 weeks, 5 subjects (1.7%) in the emtricitabine group experienced a new CDC Class C event compared to 7 subjects (2.5%) in the d4T group.

    14.3 Clinical Trial Results in Treatment-Experienced Adults

    Trial 303

    Trial 303 was a 48-week, open-label, active-controlled, multicenter clinical trial comparing emtricitabine (200 mg once daily) to 3TC, in combination with d4T or AZT and a protease inhibitor or NNRTI in 440 adult subjects who were on a 3TC-containing triple-antiretroviral drug regimen for at least 12 weeks prior to trial entry and had HIV-1 RNA ≤400 copies/mL.

    Subjects were randomized 1:2 to continue therapy with 3TC (150 mg twice daily) or to switch to emtricitabine (200 mg once daily). All subjects were maintained on their stable background regimen. Subjects had a mean age of 42 years (range 22-80); 86% were male, 64% Caucasian, 21% African-American, and 13% Hispanic. Subjects had a mean baseline CD4+ cell count of 527 cells/mm3 (range 37-1909), and a median baseline plasma HIV-1 RNA of 1.7 log10 copies/mL (range 1.7-4.0).

    The median duration of prior antiretroviral therapy was 27.6 months. Table 13 provides treatment outcomes through 48 weeks.

    Table 13. Virologic Outcomes of Randomized Treatment at Week 48 (Trial 303)

    a. Subjects achieved and maintained confirmed HIV RNA <400 copies/mL (<50 copies/mL) through Week 48.

    b. Includes subjects who failed to achieve virologic suppression or rebounded after achieving virologic suppression.

    c. Includes lost to follow-up, subject withdrawal, non-compliance, protocol violation, and other reasons.
    Outcomes
    		Emtricitabine + AZT/d4T + NNRTI/PI
    (N=294)
    		3TC + AZT/d4T + NNRTI/PI
    (N=146)
    Respondera
    		77% (67%)
    		 82% (72%)
    Virologic Failureb
    		7%
    		 8%
    Death
    		 0%
    		 <1%
    Discontinuation Due to Adverse Event
    		 4%
    		 0%
    Discontinuation for Other Reasonsc
    		12%
    		 10%

    The mean increase from baseline in CD4+ cell count was 29 cells/mm3 for the emtricitabine arm and 61 cells/mm3 for the 3TC arm.

    Through 48 weeks, in the emtricitabine group 2 subjects (0.7%) experienced a new CDC Class C event compared to 2 subjects (1.4%) in the 3TC group.

    14.4 Clinical Trial Results in Pediatrics

    In three open-label, nonrandomized clinical trials, FTC was administered to 169 HIV-1 infected treatment-naive and experienced (defined as virologically suppressed on a 3TC-containing regimen for which FTC was substituted for 3TC) subjects between 3 months and 21 years of age. Subjects received once-daily emtricitabine oral solution (6 mg/kg to a maximum of 240 mg/day) or emtricitabine capsules (a single 200 mg capsule once daily) in combination with at least two other antiretroviral agents.

    Subjects had a mean age of 7.9 years (range 0.3-21); 49% were male, 15% Caucasian, 61% Black, and 24% Hispanic. Subjects had a median baseline HIV-1 RNA of 4.6 log10 copies/mL (range 1.7-6.4) and a mean baseline CD4+ cell count of 745 cells/mm3 (range 2-2650). Through 48 weeks of therapy, the overall proportion of subjects who achieved and sustained an HIV-1 RNA <400 copies/mL was 86%, and <50 copies/mL was 73%. The mean increase from baseline in CD4+ cell count was 232 cells/mm3 (-945, +1512). The adverse reaction profile observed during these clinical trials was similar to that of adult subjects, with the exception of the occurrence of anemia and higher frequency of hyperpigmentation in children [see Adverse Reactions (6.1)].

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Emtricitabine Capsules 200mg are size '1' capsules with sky blue cap imprinted with "EMT" in black and white body imprinted with "200" in black.

    Emtricitabine Capsules, 200mg are available as follows:

    Bottles of 30 capsules (NDC: 69097-642-02)

    Bottles of 1000 capsules (NDC: 69097-642-15)

    • Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F - 86°F) [see USP Controlled Room Temperature].
    • Dispense only in original container. Keep container tightly closed.
  • 17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-approved patient labeling (Patient Information).

    Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV

    Inform patients that severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and hepatitis B virus (HBV) who have discontinued emtricitabine. Advise patients not to discontinue emtricitabine without first informing their healthcare provider. All patients should be tested for HBV infection before or when starting emtricitabine and those who are infected with HBV need close medical follow-up for several months after stopping emtricitabine to monitor for exacerbations of hepatitis [see Warnings and Precautions (5.1)].

    Immune Reconstitution Syndrome

    Inform patients that in some patients with advanced HIV infection (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms. Advise patients to inform their healthcare provider immediately of any symptoms of infection [see Warnings and Precautions (5.2)].

    Lactic Acidosis and Severe Hepatomegaly

    Inform patients that lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported. Treatment with emtricitabine should be suspended in any patient who develops clinical symptoms suggestive of lactic acidosis or pronounced hepatotoxicity [see Warnings and Precautions (5.3)].

    Pregnancy Registry

    Inform patients that there is an antiretroviral pregnancy registry to monitor fetal outcomes of pregnant women exposed to emtricitabine [see Use in Specific Populations (8.1)].

    Lactation

    Instruct mothers not to breastfeed if they are taking emtricitabine because of the risk of passing the HIV-1 virus to the baby [see Use in Specific Populations (8.2)].

    Disclaimer: Other brands listed are the registered trademarks of their respective owners and are not trademarks of Cipla Ltd.

    Manufactured by:

    Cipla Ltd., Verna Goa, India

    Manufactured for:

    Cipla USA, Inc.

    10 Independence Boulevard, Suite 300

    Warren, NJ 07059

    Revised: 3/2023

  • PATIENT PACKAGE INSERT

    PATIENT INFORMATION

    Emtricitabine (em tri SIT uh bean) Capsules

    What is the most important information I should know about Emtricitabine capsules?

    Emtricitabine can cause serious side effects, including:

    • Worsening of Hepatitis B virus infection (HBV). Your healthcare provider will test you for HBV before starting treatment with emtricitabine. If you have HBV infection and take emtricitabine, your HBV may get worse (flare-up) if you stop taking emtricitabine. A "flare-up" is when your HBV infection suddenly returns in a worse way than before.
    • Do not stop taking emtricitabine without first talking to your healthcare provider.
    • Do not run out of emtricitabine. Refill your prescription or talk to your healthcare provider before your emtricitabine is all gone.
    • If you stop taking emtricitabine, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your HBV infection, or give you a medication to treat hepatitis B. Tell your healthcare provider about any new or unusual symptoms you may have after you stop taking emtricitabine.

    For more information about side effects, see the section "What are the possible side effects of emtricitabine?"

    What are Emtricitabine capsules?

    Emtricitabine is a prescription medicine used in combination with other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection.

    HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).

    Who should not take Emtricitabine capsules?

    Do not take Emtricitabine capsules if you are allergic to emtricitabine or any of the ingredients in emtricitabine capsules. See the end of this leaflet for a complete list of ingredients in emtricitabine capusles.

    What should I tell my healthcare provider before taking emtricitabine?

    Before taking emtricitabine capsules, tell your healthcare provider about all of your medical conditions, including if you:

    • have liver problems, including HBV infection
    • have kidney problems or receive kidney dialysis treatment
    • are pregnant or planning to become pregnant. It is not known if Emtricitabine can harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with emtricitabine.
    • Pregnancy Registry : There is a pregnancy registry for women who take emtricitabine during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.
    • are breastfeeding or plan to breastfeed. Emtricitabine can pass to your baby in your breast milk. Do not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby. Talk with your healthcare provider about the best way to feed your baby

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    Some medicines may interact with emtricitabine. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

    You can ask your healthcare provider or pharmacist for a list of medicines that interact with emtricitabine. Do not start a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to take emtricitabine with other medicines.

    How should I take Emtricitabine capsules?

    • Take Emtricitabine capsules exactly as your healthcare provider tells you to take it.
    • Dosing in adults: Take emtricitabine capsules by mouth 1 time each day.
    • Dosing in children: Take emtricitabine capsules by mouth 1 time each day. The child's healthcare provider will calculate the right dose of Emtricitabine capsule based on the child's weight.
    • Emtricitabine may be taken with or without food.
    • Do not miss a dose of emtricitabine. Missing a dose lowers the amount of medicine in your blood. Refill your emtricitabine prescription before you run out of medicine.
    • Do not change your dose or stop taking emtricitabine capsules without first talking with your healthcare provider. Stay under a healthcare provider's care when taking emtricitabine.
    • If you take too much Emtricitabine capsules, call your healthcare provider or go to the nearest hospital emergency room right away.

    What are the possible side effects of emtricitabine?

    Emtricitabine may cause serious side effects, including: 

    • See "What is the most important information I should know about emtricitabine capsules?"
    • Changes in your immune system (Immune Reconstitution Syndrome) can happen whenan HIV-infected person starts taking antiretroviral medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having any new symptoms after starting emtricitabine capsules.
    • Too much lactic acid in your blood (lactic acidosis). Too much lactic acid is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you develop any of these symptoms:
    • weakness or being more tired than usual
    • being short of breath or fast breathing
    • cold or blue hands and feet
    • fast or abnormal heartbeat.
    • unusual muscle pain
    • stomach pain with nausea and vomiting
    • feel dizzy or lightheaded
    • Severe liver problems. In rare cases, severe liver problems can happen that can lead to death. Your healthcare provider may tell you to stop taking emtricitabine if you develop new or worse liver problems during treatment with emtricitabine. Tell your healthcare provider right away if you develop any of these symptoms:
    • fatigue
    • weakness
    • yellowing of your skin or the white part of your eyes (jaundice)
    • light-colored stools
    • nausea and vomiting
    • confusion
    • dark "tea-colored" urine
    • loss of appetite for several days or longer
    • stomach-area (abdominal) swelling and pain.

    The most common side effects of emtricitabine include:

    •   headache
    •   diarrhea
    •   nausea
    •   tiredness
    •   dizziness
    •   depression
    •   problems sleeping
    •   abnormal dreams
    •   rash
    •   abdominal pain
    •   weakness
    •   cough
    •   runny nose

    Skin discoloration in children may also happen with emtricitabine.

    These are not all the possible side effects of emtricitabine.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    How do I store Emtricitabine capsules?

    • Store Emtricitabine capsules between 59 °F and 86 °F (15°C to 30°C).
    • Keep emtricitabine capsules in the original container and keep the container tightly closed.
    • Do not use emtricitabine capsules if seal over bottle opening is broken or missing.

    Keep emtricitabine capsules and all other medicines out of reach of children.

    General information about the safe and effective use of emtricitabine:

    Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use emtricitabine for a condition for which it was not prescribed. Do not give emtricitabine to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about emtricitabine that is written for health professionals.

    What are the ingredients of Emtricitabine capsules?

    Active Ingredient: emtricitabine

    Inactive Ingredients for Emtricitabine capsules: mannitol, hypromellose, and magnesium stearate. The capsules are printed with ink containing black iron oxide.

    Disclaimer: Other brands listed are the registered trademarks of their respective owners and are not trademarks of Cipla Ltd.

    Manufactured by:

    Cipla Ltd., Verna Goa, India

    Manufactured for:

    Cipla USA, Inc.

    10 Independence Boulevard, Suite 300

    Warren, NJ 07059

    Revised: 3/2023

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC: 69097-642-02

    Rx Only 30 Capsules

    Emtricitabine Capsules

    200 mg

    Cipla

    emtri-30-bottle-label

    NDC: 69097-642-15

    Rx Only 1000 Capsules

    Emtricitabine Capsules

    200 mg

    Cipla

    1000s pack
  • INGREDIENTS AND APPEARANCE
    EMTRICITABINE 
    emtricitabine capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 69097-642
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    EMTRICITABINE (UNII: G70B4ETF4S) (EMTRICITABINE - UNII:G70B4ETF4S) EMTRICITABINE200 mg
    Inactive Ingredients
    Ingredient NameStrength
    MANNITOL (UNII: 3OWL53L36A)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    GELATIN (UNII: 2G86QN327L)  
    HYPROMELLOSE 2910 (15 MPA.S) (UNII: 36SFW2JZ0W)  
    SODIUM LAURYL SULFATE (UNII: 368GB5141J)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Product Characteristics
    ColorWHITE (White body; Skybluecap) Scoreno score
    ShapeCAPSULE (size 1) Size19mm
    FlavorImprint Code EMT;200
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 69097-642-151000 in 1 BOTTLE; Type 0: Not a Combination Product08/31/2020
    2NDC: 69097-642-0230 in 1 BOTTLE; Type 0: Not a Combination Product08/31/2020
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA09116808/31/2020
    Labeler - Cipla USA Inc. (078719707)
    Registrant - Cipla USA Inc. (078719707)
    Establishment
    NameAddressID/FEIBusiness Operations
    CIPLA LIMITED GOA650072015manufacture(69097-642) , analysis(69097-642) , label(69097-642) , pack(69097-642)
    Establishment
    NameAddressID/FEIBusiness Operations
    CIPLA LIMITED KURKUMBH917066446api manufacture(69097-642) , analysis(69097-642)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.